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Abstract
Background: Autoimmune lymphoproliferative syndrome (ALPS) is a rare inherited disorder
characterized by defective function of Fas, autoimmune manifestations that predominantly involve
blood cells, polyclonal accumulation of lymphocytes in the spleen and lymph nodes with
lymphoadenomegaly and/or splenomegaly, and expansion of TCRαβ+ CD4/CD8 double-negative
(DN) T cells in the peripheral blood. Most frequently, it is due to Fas gene mutations, causing ALPS
type Ia (ALPS-Ia). However, other mutations, namely of the FasL gene (ALPS-Ib) and the caspase-
10 gene (ALPS-II) are occasionally detected, whereas some patients do not present any known
mutations (ALPS-III). Recently, mutations of the NRAS gene have been suggested to cause ALPS-IV.
Results: This work reports two patients that are combined heterozygous for single nucleotide
substitutions in the Fas and caspase-10 genes. The first patient carried a splice site defect
suppressing allele expression in the Fas gene and the P501L substitution in caspase-10. The second
had a mutation causing a premature stop codon (Q47X) in the Fas gene and the Y446C substitution
in caspase-10. Fas expression was reduced and caspase-10 activity was decreased in both patients.
In both patients, the mutations were inherited from distinct healthy parents.
Conclusion: These data strongly suggest that co-transmission of these mutation was responsible
for ALPS.
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Background
Autoimmune lymphoproliferative syndrome (ALPS) is a
rare inherited disorder characterized by autoimmune
manifestations that predominantly involve blood cells,
polyclonal accumulation of lymphocytes in the spleen
and lymph nodes with lymphoadenomegaly and/or
splenomegaly, expansion of TCRαβ+ CD4/CD8 double-
negative (DN) T cells in the peripheral blood and defec-
tive in vitro apoptosis of mature lymphocytes induced by
the Fas death receptor [1-4]. Individuals with ALPS also
have an elevated incidence of several types of lymphoma
[5].
Fas belongs to the Tumor Necrosis Factor Receptor
(TNFR) superfamily and induces cell death upon trigger-
ing by FasL [6,7]. It is highly expressed by activated effec-
tor lymphocytes in the immune response and switches it
off by limiting clonal expansion of lymphocytes and
favoring peripheral tolerance. Fas signaling starts from
aggregation of Fas, the adaptor molecule FADD (Fas-asso-
ciated death domain protein), and caspase-8 forming the
Death Inducing Signaling Complex (DISC) which triggers
caspase-8 activation and induces cell apoptosis through
two partly interconnected pathways; the extrinsic pathway
involves caspase-8-mediated direct activation of the cas-
cade, whereas the intrinsic pathway proceeds through
mitochondrial release of cytochrome c and activation of
caspase-9. Both pathways converge in the activation of
effector caspases, such as caspase-3, -6 and -7. In humans,
but not in mice, the extrinsic pathway also involves cas-
pase-10, that is recruited into the DISC and cooperates
with caspase-8 in activation of the caspase cascade [8-10].
ALPS is generally due to deleterious mutations of the Fas
gene (TNFRSF6) and is classified as ALPS type-Ia (ALPS-
Ia) [11,12]. Other mutations, namely of the FasL gene in
ALPS-Ib [13-15], and the caspase-10 gene (CASP10) in
ALPS-II [16,17], are occasionally detected, whereas some
patients do not present any known mutations (ALPS
III)[1-3,18-20]. Recently, mutations of the NRAS gene
have been suggested to cause a further type of ALPS (ALPS-
IV) [21]. ALPS does not behave as a classical monogenic
disease. Most ALPS type-Ia patients are heterozygous for
the Fas mutation, but the parent carrying the mutation is
generally healthy. Other complementary factors may thus
be required in function of the severity of the mutation
[22]. One possibility is that mild Fas mutations only
induces ALPS when cooperate with mutations of other
genes impairing function of the Fas system itself or other
systems involved in similar functions. In line with this
possibility, we have described osteopontin and perforin
gene variations that predispose to ALPS [23,24]. The oste-
opontin gene variation correlated with production of
increased amounts of this cytokine, which is involved in
inflammation and also inhibits activation-induced cell
death. The perforin gene variations were associated with
decreased function of cytotoxic cells, which may switch
off the immune response by fratricide of effector lym-
phocytes.
This work describes two unrelated patients that are double
heterozygous for mutations of the Fas and the caspase-10
gene. Since the two mutations were inherited from dis-
tinct healthy parents, their co-transmission probably
resulted in ALPS.
Results
Analysis of TNFRSF6 and CASP10
Pt.1 showed a heterozygous nucleotide substitution in
TNFRSF6 (c334 -2a>g, [Genbank NM_000043.3]) located
in the splicing-acceptor site in the third intron and deter-
mining the IVS3-2a>g splice site defect. The mutation
results in skipping of exon 4, coding for an extracellular
cysteine-rich domain, frameshift and premature termina-
tion after 38 codons. The mutated allele produces no pro-
tein. This mutation had already been described in a
homozygous ALPS patient, whose heterozygous parents
were healthy [25,26].
Sequencing of CASP10 detected a C>T substitution at
nt1502 in exon 10 [Genbank NM_032977.2] resulting in
a proline to leucine change (P501L) in the small catalytic
subunit of caspase. The mutation, not previously
described, was not detected in 80 healthy donors nor in
40 other ALPS patients. Family analysis showed that the
CASP10 mutation was inherited from the apparently
healthy mother, who did not carry the TNFRSF6 muta-
tion. This was presumably inherited from the father, who
was not available for analysis, or was a de novo mutation.
Pt.2 carried a heterozygous C>T substitution at nt139 in
TNFRSF6. It was located in exon 2 coding for an extracel-
lular domain and created a premature stop codon
(Q47X). The mutation was predicted to cause haploinsuf-
ficiency due to nonsense mediated decay of the aberrant
mRNA; alternatively, a truncated soluble Fas fragment
might be produced. Sequencing of CASP10 detected a het-
erozygous nucleotide substitution (1337A>G) in exon 9
causing the Y446C amino acid change in the predicted
protease domain of the small subunit. This variation has
been previously associated to ALPS, but has been reported
also in the healty Caucasian population with allelic fre-
quency ranging from 1.6 to 2% [17,20]. Family analysis
showed that the Fas mutation was inherited from the
apparently healthy mother; the CASP10 variation was
possibly inherited from the father, who was not available
for the study.
The pedigrees of these families are shown in the Figure 1.BMC Immunology 2007, 8:28 http://www.biomedcentral.com/1471-2172/8/28
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Functional analysis of the mutations
Analysis of Fas function in PHA-activated T cells from the
patients and their mothers showed that it was defective in
Pt.1 and borderline in Pt.2 since cell survival upon trigger-
ing of Fas was 92% in the former and 78% in the latter
(normal values: median 60%, 95th percentile 82%). More-
over, Fas function was borderline in both mothers since
cell survival was 80% in the Pt.1's mother and 78% in the
Pt.2 mother (Fig. 1).
To asses whether the IVS3-2a>g and Q47X TNFRSF6
mutations affected Fas expression, activated T cells from
Pt.1 and Pt.2 were stained by direct immunofluorescence
with an anti-Fas mAb and analyzed by flow cytometry.
Results showed that both patients displayed decreased Fas
expression (Fig. 2a).
To assess whether the P501L and Y446C caspase-10
amino acid substitutions affected the enzyme function,
we evaluated caspase-10 activity induced by triggering of
Fas with anti-Fas mAb in activated T cells from available
mutated subjects, i.e. Pt.1, his mother, and Pt.2. All sub-
jects showed a caspase-10 activity that was lower than that
of the controls (Fig. 2b). These data suggest that both sub-
stitution decrease caspase-10 activity. Data on Y446C are
in line with those previously reported [17] showing that
the cloned Y446C-caspase-10 is less effective than the wild
type form in restoring Fas-mediated apoptosis in cells
lacking endogenous caspases-8 and -10, but does not exert
dominant negative activity on the wild type.
To further assess the activity of the novel P501L-caspase-
10, the cDNAs coding for it or the wild-type protein (iso-
form d) were cloned into the pcDNA3.1 Myc-His vector,
fused to HA- or FLAG-tag sequences respectively (P501LHA
and WTFLAG plasmids). Both were transiently transfected
into 293T cells, expressing minimal levels of endogenous
caspase-10. Moreover, 293T cells were cotrasfected with
the P501LHA and WTFLAG plasmids to determine whether
the mutated form exterted a dominant negative activity on
the wild type form. Western blot analysis showed that
both constructs were expressed at comparable levels in all
trasfectants and both proteins were spontaneously
cleaved, the mutated form even more efficiently than the
wild type form (Fig. 3). However, analysis of the caspase-
10 enzyme activity on the lysates by a fluorimetric assay
Pedigrees of Family 1 and Family 2 Figure 1
Pedigrees of Family 1 and Family 2. Inheritance of the CASP10 and TNFRSF6 mutations and electropherograms of the 
sequences performed on the genomic DNA of Pt.1 and Pt.2. Circles represent females; squares, males; subjects carrying a 
CASP10 mutation are marked in black, those with a TNFRSF6 are marked with striped lines. Numbers indicate the cell survival 
upon Fas triggering by mAb in T cell lines generated form each subject; Fas function was defective in Pt.1 and borderline in the 
other subjects (normal values of cell survival: median 60%, 95th percentile 82%)BMC Immunology 2007, 8:28 http://www.biomedcentral.com/1471-2172/8/28
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showed that the P501L-caspase-10 displayed about 50%
of the activity displayed by the wild type. Cells cotrans-
fected with the P501LHA and WTFLAG plasmids showed lev-
els of caspase-10 activity intermediate between those of
cells transfected with each plasmid alone, which indicates
that the mutated form does not exert a dominant negative
activity on the wild type.
Discussion
This work reports that mutations of TNFRSF6, characteriz-
ing ALPS type Ia, and CASP10, characterizing ALPS type II,
can cooperate in the development of ALPS.
Fas mutations are the most frequent in ALPS. Usually het-
erozygous, their penetrance depends on their effect on Fas
function. Mutations hitting the intracellular death
domain of Fas, involved in recruitment of FADD and cas-
pase-8 and initiating the death signal, are often the most
severe. They exert a dominant-negative effect and display
Fas expression and caspase-10 activity in subjects carrying the TNFRSF6 and CASP10 mutation Figure 2
Fas expression and caspase-10 activity in subjects carrying the TNFRSF6 and CASP10 mutation. a) Fas expres-
sion was evaluated in T cell lines obtained by activating PBMC with PHA (1 µg/ml) and cultured for 6 days in RPMI 1640 +10% 
FCS+rIL-2 (2 U/mL). Before activation (day 0), and at day 3 and day 6 of culture, cells were stained with a FITC-conjugated 
anti-Fas mAb and analyzed with a cytofluorimeter. The upper panel shows the cytofluorimetric staining of cells from Pt.1, Pt.2, 
and a control donor after 6 days of culture. The lower panel shows the MFI ratio calculated for each subject at different times of 
culture. Control data are the medians ± interquartile ranges (25–75% range) from 5 control donors; their 5th percentile value 
at day 6 was MFI-R = 6.48. b) Caspase-10 activity was evaluated in PHA-activated T cells cultured for 12 days (see Methods) in 
RPMI 1640 +10% FCS+rIL-2 (10 U/mL) and then treated or not with an anti-Fas mAb for 3 hours. Results are expressed as rel-
ative caspase activity % calculated as follows: (result displayed by each subject/mean of the results displayed by the 2 controls 
run in the same experiment) × 100; 100% indicates the mean of the results obtained with the 2 control donors run in parallel 
with the patient samples in each experiment; the dotted horizontal lines indicate the 5th percentile of the activity displayed by 
all normal controls. The color code is the same in all panels.BMC Immunology 2007, 8:28 http://www.biomedcentral.com/1471-2172/8/28
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Caspase-10 activity in 293T cells transfected with P501L-caspase-10 Figure 3
Caspase-10 activity in 293T cells transfected with P501L-caspase-10. Analysis of 293T cells transiently transfected 
with the mock, WTFLAG, P501LHA, or P501LHA+WTFLAG plasmids, as indicated in the panel. a) Western blot analysis of cell 
transfectant lysates performed with anti-caspase-10 antibody; expression of the transfected molecules was confirmed using 
anti-HA and -FLAG antibodies (data not shown). The white arrow shows the pro-caspase-10; black arrows indicate the cleaved 
forms. b) Fluorimetric enzyme assay of caspase-10 activity evaluated in the cell transfectant lysates 24 h after transfection; data 
are relative to those displayed by mock-transfected cells (indicated as 100%) and are the means ± SE of data from 6 independ-
ent experiments. The asterisks mark the data significantly different from those obtained with P501LHA-transfected cells (p < 
0.01, Mann Whitney test).BMC Immunology 2007, 8:28 http://www.biomedcentral.com/1471-2172/8/28
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high penetrance. By contrast, mutations hitting the extra-
cellular portion or causing haploinsufficiency have
weaker penetrance [22,27].
Both our patients carried mutations predicted to cause
haploinsufficiency. In line with this prediction, T cells
from both Pt.1 and Pt.2 expressed low levels of Fas. Pene-
trance of these mutations is presumably weak. This is sug-
gested for the nonsense Q47X mutation by the lack of any
sign of ALPS in the Pt.2's carrier mother. By contrast, the
absence of Pt.1's father meant that clinical effect of IVS3-
2a>g splice site defect could not be determined by a pedi-
gree analysis, since it might have been a de novo muta-
tion. However, this mutation has been previously
described in a different family, where its heterozigosity
was not sufficient to cause ALPS [26].
Only two CASP10 mutations have so far been unequivo-
cally involved in ALPS. They are the missense mutations
causing the L285F and I406L amino acid substitutions
detected in 1 and 3 heterozygous patients respectively.
Both mutations decreased caspase-10 activity and exerted
a dominant negative effect on the wild type protein, but
neither was sufficient to induce the overt disease, since
several mutated familial components were healthy, and
some displayed serum autoantibodies only [16,17].
Both CASP10 mutations carried by our patients are mild
heterozygous missense mutations decreasing caspase-10
activity without exerting a dominant negative effect on the
wild type protein. It is therefore intriguing that these
patients also displayed mild Fas mutations that were pre-
sumably required to worsen the apoptotic defect and
cause ALPS development. Pt.2 carried the Y446C muta-
tion, previously reported in one heterozygous patient dis-
playing a mild form of ALPS [17]. This mutation
decreased caspase-10 function, without inducing a domi-
nant negative effect on the wild type protein. The muta-
tion is not sufficient to induce ALPS since it is also
detected in 1–2% of the healthy Caucasian population
[17,20]. Pt.1 carried the novel P501L mutation, located,
like Y466C, in the small subunit of caspase-10. P501L,
too, decreased caspase-10 function without inducing a
dominant negative effect on the wild type protein.
Decreased activity was clearly detected in lymphocytes
from both this patient, who also carried the Fas mutation,
and his mother, who only carried the CASP10 mutation.
Moreover, 293T cells transfected with the mutated form
displayed about 50% of the enzyme activity displayed by
the wild type. Lack of negative dominance was shown
when cotransfection with both the mutated and the wild
type forms produced an additive and not an antagonistic
effect on caspase-10 enzyme activity. It is noteworthy that
western blot analysis of transfected cells showed that
P501L did not affect cleavage of caspase-10, which is often
interpreted as an evidence of activation. However, the
decreased activity detected by the in vitro caspase-10
enzyme assay supports the model proposed by Boatright
et al. that cleavage is neither sufficient or necessary for
activation of initiator caspases, that mainly depends on
dimerization [28].
The effect of the interaction between these Fas and cas-
pase-10 mutations seems opposite to those reported for
interactions between Fas mutations and caspase-10 mis-
sense variation V410I [16,17]. This variation was initially
posited as a cause of ALPS since it had been detected in
one homozygous patient. It has since been found as an
"innocent" polymorphism carried by 3–5% of the Cauca-
sian population [16,17,29]. An association analysis,
indeed, suggested that it gave protection against severe
ALPS in 63 families with ALPS-Ia caused by severe domi-
nant mutations of Fas [17]. It is intriguing that the first
ALPS patient homozygous for V410I harbored a hetero-
zygous missense mutation in the tumor necrosis factor
receptor-1 gene (TNFRSF1A), which is mutated in the TNF
receptor-associated periodic fever syndrome (TRAPS) and
may explain its clinical pattern [30]. This suggests that the
caspase-10 variation also influenced the clinical pheno-
type due to the TNFRSF1A mutation.
Conclusion
This work suggests that ALPS may sometimes be caused by
the concurrent effect of mutations hitting different genes
involved in Fas function and hence that it may be both a
classic monogenic disease, as occurs in the presence of
severe mutations hitting the intracellular portion of Fas,
and the outcome of digenic or even oligogenic mutations
affecting different steps of the Fas signalling pathway.
Methods
Patients
Patient 1 (Pt.1) was a 27-year-old Caucasian male. At the
age of 23, he presented fever of unknown origin associ-
ated with mucositis, weight loss and nocturnal sweating.
Laterocervical, axillary and inguinal lymphadenopathies
with hepatomegaly and splenomegaly were clinically dis-
closed. Blood analyses showed reduced white blood cell
and platelet counts, borderline hemoglobin levels, posi-
tive Coombs test and hypergammaglobulinemia, and
expansion of DN T cells in the peripheral blood (6%).
Histopathologic examination of left axillary lymph nodes
showed reactive follicular hyperplasia with regular distri-
bution of T- and B-dependent areas. Defective Fas-
induced apoptosis of lymphocytes in cell death assays
pointed to ALPS. Oral steroids improved the clinical pic-
ture, reduced lymph nodes and spleen size, and increased
the platelet count and hemoglobin level.BMC Immunology 2007, 8:28 http://www.biomedcentral.com/1471-2172/8/28
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Patient 2 (Pt.2) was a 12-year-old Caucasian male who
displayed an ALPS phenotype at the age of 3, with late-
rocervical lymphadenopathy, mild hepatosplenomegaly,
immune neutropenia and thrombocytopenia. His-
topathologic examination of a submaxillary lymph node
demonstrated follicular hyperplasia. DN T cells were 3.6%
and Fas-induced lymphocyte apoptosis was borderline.
Blood analyses also showed increased IgM and IgA levels
and lupus anticoagulant. At the age of 4, he developed
transient mild hemolytic anemia; hematological altera-
tions spontaneously remitted at the age of 5, but laterocer-
vical adenopathy increased to bulky masses. The left
submaxillary and cervical lymph nodes began to com-
press the upper airways and were excised when he was ten
years old; he is now in hematological remission, with per-
sisting bulky laterocervical lymphadenopathies. The
patient's father died of peritoneal carcinosis at 33. The
paternal grandfather had died of gastric cancer.
Sequence analysis
Genomic DNA was extracted from PBMCs by standard
methods (Pure Gene DNA Isolation Kit, Gentra Biosystem
Unc, Minneapolis, Minnesota) after informed consent. All
coding exons and intron-exon boundaries of TNFRSF6
[Genbank AY450925.1] and CASP10 [Genbank
NT_005403.14] were amplified by polymerase chain reac-
tion (GeneAmp PCR System 9700, Applied Biosystems,
Foster City, CA); primer sequences and annealing temper-
atures for each primers pair used for amplification were
previously reported [20,31]. The PCR products were
sequenced with the BigDyeTM Terminator Kit (Applied
Biosystems,) on an ABI PRISM 3100 Genetic Analyzer
(Applied Biosystems) using the same primers. The family
segregation of mutations was ascertained by enzymatic
digestion.
Fas function assay
Fas-induced cell death was evaluated as previously
reported on T cell lines obtained by activating PBMCs
with PHA at days 0 (1 µg/ml) and 15 (0.1 µg/ml) and cul-
tured in RPMI 1640 + 10% FCS + rIL-2 (2 U/ml) (Biogen,
Geneva, Switzerland). Fas function was assessed 6 days
after the second stimulation (day 21) [18,19]. Cells were
incubated with control medium or anti-Fas mAb (CH11,
IgM isotype) (1 µg/ml) (UBI, Lake Placid, NY) in the pres-
ence of rIL-2 (1 U/ml) to minimize spontaneous cell
death. Cell survival was evaluated after 18 h by counting
live cells in each well by the trypan blue exclusion test and
by flow cytometry of cells excluding propidium iodide
and unstained by annexin V-FITC; the two methods gave
overlapping results. Assays were performed in duplicate.
Cells from two normal donors were included in each
experiment as positive controls. Results were expressed as
specific cell survival %, calculated as follows: (total live
cell count in the assay well/total live cell count in the con-
trol well) × 100. Fas function was defined as defective
when cell survival was >82 % (the 95th percentile of data
obtained from 200 normal controls).
Immunophenotype analysis
Expression of surface molecules was evaluated by direct
immunofluorescence and flow cytometry (FACScan. Bec-
ton Dickinson, San Jose, CA). The following mAb were
used: anti-CD4 (Leu-3a), -CD8 (Leu-2a), -TCRαβ (Becton
Dickinson), and -Fas (Immunotech, Marseilles, France).
CD4 and CD8 DN TCRαβ-positive cells were detected by
2-color immunofluorescence with fluorescein isothiocy-
anate (FITC)-conjugated anti-TCRαβ mAb and phyco-
erythrin (PE)-conjugated anti-CD4 and anti-CD8 mAbs.
Fas was detected by 2-color immunofluorescence on rest-
ing or activated T cells, using PE-conjugated anti- TCRαβ
mAb and FITC-conjugated anti-Fas mAb (Chemicon,
Temecula, CA). Nonspecific background fluorescence was
established with the appropriate isotype-matched control
mAb (Becton Dickinson)
Caspase-10 activity
PBMCs were activated with PHA at days 0 (1 µg/ml) and
8 (0.1 µg/ml) and cultured in RPMI 1640 + 10% FCS + rIL-
2 (10 U/ml). Four days after the second stimulation, 6 ×
106 T cells were treated or not with anti Fas mAb (CH11,
IgM isotype) (1 µg/ml) on ice for 30 min, then moved to
37°C for 3 h and centrifuged. At least 2 control samples,
using T cells from different healthy donors, were always
run in parallel. Caspase-10 activity of T-cells and trans-
fected 293T was assessed in cell lysates using a fluorimet-
ric assay (MBL, Watertown, MA).
Caspase-10 cloning
cDNA coding for wild type caspase-10 was obtained as
previously reported [16]. To obtain the cDNA of mutated
caspase-10, we amplified the fragment containing the
P501L mutation, from 1055 bp to 1569 bp [Genbank
NM_032977.2] by RT-PCR. Briefly, total RNA extracted
from patient's PBMC was reverse-transcribed with the
ThermoScript RT-PCR system (Invitrogen, Milan, Italy)
and amplified with primers C10 NcoI-fw and C10 XhoI-
rev (Table 1). The fragment from ATG to 1055 bp was
obtained from the wild type clone by PCR using a 5'-
primer adding the HA TAG (C10HA-fw/C10 NcoI-rev). In
order to discriminate between the wild type and the
mutated form, we added the FLAG TAG to the wild type
clone by PCR (C10FLAG-fw/NcoI-rev). Both cDNAs were
then cloned into the pcDNA3.1 Myc-His vector (Invitro-
gen) and sequenced.
Transient Transfection and Western Blotting
Human embryonic kidney 293T cells (ATCC #CRL-
11268) were cultured in Dulbecco's modified essential
medium (DMEM) supplemented with 10% FCS at 37°C.BMC Immunology 2007, 8:28 http://www.biomedcentral.com/1471-2172/8/28
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3 × 106 cells were plated in 10 cm dishes and transfected
with 24 µg of the empty vector, the WTFLAG vector, the
P501LHA vector, or a mix of them by Lipofectamine 2000
kit (Invitrogen). After 24 h, adherent and floating cells
were harvested in lysis buffer (MBL) for 30 min. Cell
debris were removed by centrifugation and equal
amounts of the cleared lysates were heated for 5 min at
95°C. Protein extracts were then separated by SDS-PAGE,
transferred to Hybond-C extra membranes (Ge Health-
care, Piscataway, NJ, USA), blotted with anti-caspase-10
(1 µg ml-1) (MBL), anti-HA (1 µg ml-1) (Santa Cruz Bio-
technology, Santa Cruz, CA, U.S.A.), anti-FLAG (1 µg ml-
1) (Sigma, Milan, Italy), anti-tubulin (1 µg ml-1) (Sigma)
and a peroxidase-conjugated anti-mouse or rabbit anti-
bodies (Ge Healthcare), and revealed by chemilumines-
cence.
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